Overview

Evaluation of Gadoterate in Patients With Decreased Kidney Function

Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study is for individuals with decreased kidney function whose doctor has ordered Magnetic Resonance Imaging (MRI). Because kidney function is decreased, these patients usually do not receive the intravenous contrast material that can improve the accuracy of the MRI findings. The purpose of this study is to evaluate the safety and benefit of using a contrast material called Gadoterate in patients with decreased kidney function.
Phase:
Phase 4
Details
Lead Sponsor:
Loyola University
Collaborator:
Guerbet
Treatments:
Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
Pancrelipase